Inhibrx Stock News

SAN DIEGO , April 5, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that

Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to year-ago quarter EPS of

The U.S. Food and Drug Administration granted orphan drug designation to Inhibrx''s <> INBRX-101 to treat alpha-1 antitrypsin deficiency, or AATD

SAN DIEGO, March 3, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-101…

Inhibrx press release (NASDAQ:INBX): Q4 GAAP EPS of -$0.55 beats by $0.02.Revenue of $2.86M (+2.9% Y/Y) beats by $1.15M.

SAN DIEGO, Feb, 28, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2021 and provided an update on recent corporate…

SAN DIEGO , Feb. 22, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX ), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that it has amended its loan and security agreement with Oxford Finance LLC ("Oxford"). "This amendment further strengthens our balance sheet in a volatile equity market and provides us with additional non-dilutive capital and flexibility as we continue to advance our pipeline and prepare for potential commercialization," said Kelly Deck , Chief Financial Officer of Inhibrx. "Oxford has been a supportive partner throughout our evolution and transformation as a company and we are pleased to expand the relationship." The amendment provides for four additional tranches of term loans for up to an additional $130 million as follows: $40 million principal amount funded upon the closing of the amendment; $30 million , funded upon initiation of Part 4 of the Phase 1 clinical trial of INBRX-105, our PD-L1x4-1BB tetravalent conditional agonist; $30 million , funded upon the receipt of positive topline data from the Phase 1 clinical trial of INBRX-101, our AAT-Fc fusion protein for the treatment of Alpha-1 antitrypsin deficiency, or AATD; and $30 million , funded upon

Inhibrx <> shares have approached the lowest level since June 2021 after the company announced the resignation of its Vice President and Chief Medical Officer, Dr

Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, disclosed a stake in Amylyx Pharmaceuticals Inc. ( AMLX , Financial) late last week.

Inhibrx Inc (NASDAQ: INBX) announced initial results from Part 3 (combination dose escalation) of the Phase 1 trial of INBRX-106 combined with Keytruda for solid tumors.  The dose of INBRX-106 was

Inhibrx, Inc. (NASDAQ:INBX)s stock price was up 6.1% during mid-day trading on Wednesday . The company traded as high as $44.72 and last traded at $44.53. Approximately 7,944 shares changed hands during trading, a decline of 96% from the average daily volume of 184,769 shares. The stock had previously closed at $41.97. A number of []

Inhibrx, Inc. (INBX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Inhibrx, Inc. (NASDAQ:INBX) shares were up 7.2% on Thursday . The stock traded as high as $43.49 and last traded at $43.49. Approximately 235 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 177,465 shares. The stock had previously closed at $40.58. Several research analysts have weighed in []

DUBLIN--(BUSINESS WIRE)--The "TRAIL Receptor 2 Agonists - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com''s offering. This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further high

Shares of Inhibrx, Inc. (NASDAQ:INBX) shot up 4% on Friday . The company traded as high as $39.94 and last traded at $39.94. 293 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 173,792 shares. The stock had previously closed at $38.41. A number of brokerages recently weighed […]